4D Molecular Therapeutics Inc. logo

4D Molecular Therapeutics Inc.

FDMT | NASDAQ
Chart Builder DCF Calculator
$15.24
+$0.02 (+0.13%)
At close: Sep 21, 2026, 4:00 PM ET
$15.17
-$0.07 (-0.46%)
After-hours: Sep 21, 2026, 7:30 PM ET

Market Data

Market Cap
$795.64M
Enterprise Value
$454.99M
Beta
2.73
Average Volume
897.13K
Shares Outstanding (Diluted)
70.27M
Shares Change YoY
25.65%
Institutional Ownership
74.45%
Exchange
NASDAQ
ISIN
US35104E1001

Price Performance

Price Change 1M
-2.8%
Price Change 3M
31.4%
Price Change 6M
54.3%
Price Change YTD
108.2%
Price Change 1Y
106.0%
Price Change 3Y
9.6%
Price Change 5Y
-56.7%
1M CAGR (ann.)
44.3%
1Y CAGR (ann.)
128.5%
5Y CAGR (ann.)
-14.7%
All-Time CAGR
-15.6%

Valuation

PE Ratio
-5.60
Forward PE
N/A
PEG Ratio
-0.38
Forward PEG
5.03
PS Ratio
9.03
Forward PS
43.40
PB Ratio
1.95
P/FCF Ratio
-5.09
P/Adj. FCF Ratio
-4.50
P/OCF Ratio
-6.86
EV/Sales
5.16
EV/EBIT
-3.95
EV/EBITDA
-2.43
EV/FCF
-2.90
Earnings Yield
-17.9%
FCF Yield
-19.7%
Adj. FCF Yield
-22.2%

Financial Health

Net Cash
$341.7M
Total Debt
$19.63M
Cash & Short-Term Investments
$361.33M
Total Assets
$492.62M
Current Ratio
8.03
Quick Ratio
8.03
Debt / Equity Ratio
0.10
Debt / EBITDA
-0.11
Debt / FCF
-0.13
OCF / Debt
-7.95
Interest Coverage
0.00
Altman Z-Score
3.40
Piotroski F-Score
4

Margins & Profitability

Gross Profit Margin
42.0%
Operating Profit Margin
-223.4%
EBITDA Margin
-200.9%
Net Profit Margin
-194.7%
FCF Margin
-177.6%
Adj. FCF Margin
-200.7%
SBC / Revenue
22.2%
SBC Impact (per share)
-13.0%

Returns

Return on Assets
-36.4%
Return on Equity
-41.3%
Return on Invested Capital
-43.8%
Return on Capital Employed
-44.3%
Return on Tangible Assets
-36.4%

Historical Growth (CAGR)

Revenue CAGR 3Y
238.0%
Revenue CAGR 5Y
30.8%
Revenue CAGR 10Y
N/A
EPS CAGR 3Y
-6.3%
EPS CAGR 5Y
3.4%
EPS CAGR 10Y
N/A
FCF CAGR 3Y
-25.2%
FCF CAGR 5Y
-15.7%
FCF CAGR 10Y
N/A

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
14
EPS Growth Next 3Y
-4.0%
Revenue Growth Next 3Y
29.1%
Earnings Date
Nov 9, 2026
EPS Estimate (next Q)
-$1.04
EPS Growth Est (next Q)
3.0%
Revenue Est (next Q)
$3.46M
Revenue Growth Est (next Q)
3748.3%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$26
Price Target Upside
70.6%

Cash Flow

Operating Cash Flow
$-156.07M
Free Cash Flow
$-156.67M
Adj. Free Cash Flow
$-177.08M
FCF Per Share
-$2.23
OCF Per Share
-$2.22
OCF/S Ratio
-169.6%

Income Statement

Revenue
$88.23M
Gross Profit
$36.95M
Operating Income
$-197.12M
EBITDA
$-186.96M
Net Income
$-179.18M
EPS (Diluted)
-$2.72
Revenue / Employee
$450.14K
Profit / Employee
$-914.16K
Employees
196

© 2026 bestshares.com. All rights reserved.